About BLPH

Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases. The Company is currently developing two product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery device. The first is for the treatment of PAH, for which the Company intends to commence Phase 3 clinical trials in 2015, and the other for the treatment of PH-COPD, which is in Phase 2 development. The Company is also reviewing alternative paths forward for its Bioabsorbable Cardiac Matrix program.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

BLPH is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
VTI Vanguard Total Stock Market ETF 108.6 B 1.086E+11 3,570 3570 0.0% 0 64 K 63678
VXF Vanguard Extended Market ETF 6.5 B 6.5E+09 3,237 3237 0.0% 0 25 K 24505
IWC iShares Microcap ETF 852.8 M 8.52758E+08 1,426 1426 0.0% 0 36 K 36428